Molecule Details
| InChIKey | XCUAIINAJCDIPM-XVFCMESISA-N |
|---|---|
| Canonical SMILES | O=c1nc(NO)ccn1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 6.94 |
| Source | BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB15660 |
|---|---|
| Drug Name | N4-Hydroxycytidine |
| CAS Number | 3258-02-4 |
| Groups | experimental |
| ATC Codes | nan |
| Description | N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage.[A193023] It has shown antiviral activity against Venezuelan equine encephal... |
Categories: Carbohydrates Cytosine Nucleotides Experimental Unapproved Treatments for COVID-19 Glycosides Nucleic Acids, Nucleotides, and Nucleosides Nucleosides Pyrimidine Nucleosides Pyrimidines Ribonucleosides
Cross-references: CHEMBL2178720 ChemSpider: 170635 PDB: U56
Target Activities (2)
| Target | Gene | Organism | Category | Pfam | pChEMBL | Type | Source |
|---|---|---|---|---|---|---|---|
| P0DTD1 | rep | Severe acute respiratory syndrome coronavirus 2 | Pathogen | PF13087 PF16251 PF11501 PF12379 PF12124 PF11633 PF06471 PF06460 PF09401 PF20631 PF20633 PF20632 PF19215 PF19216 PF19219 PF19211 PF19218 PF16348 PF19217 PF19213 PF08716 PF08717 PF08710 PF08715 PF06478 PF01661 PF05409 PF00680 | 7.0 | IC50 | BindingDB |
| A0A1L2E0X0 | orf1a | Middle East respiratory syndrome-related coronavirus | Pathogen | PF16251 PF11501 PF11633 PF09401 PF19212 PF19211 PF19218 PF16348 PF19217 PF19213 PF08716 PF08717 PF08710 PF08715 PF01661 PF05409 | 6.8 | IC50 | BindingDB |